AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Patients With Malignancy: Commentary

Jordan E. Axelrad, Jana G. Hashash, Steven H. Itzkowitz

Research output: Contribution to journalArticlepeer-review

Abstract

Description: The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update (CPU) Commentary is to discuss the risks of various malignancies in patients with inflammatory bowel diseases (IBD) and the impact of the available medical therapies on these risks. The CPU will also guide the approach to the patient with IBD who develops a malignancy or the patient with a history of cancer in terms of IBD medication management. Methods: This CPU was commissioned and approved by the AGA Institute CPU committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership and underwent internal peer review by the CPU committee and external peer review through standard procedures of Clinical Gastroenterology and Hepatology. This communication incorporates important and recently published studies in the field, and it reflects the experiences of the authors who are experts in the diagnosis and management of IBD.

Original languageEnglish
Pages (from-to)1365-1372
Number of pages8
JournalClinical Gastroenterology and Hepatology
Volume22
Issue number7
DOIs
StatePublished - Jul 2024

Keywords

  • Biologics
  • Cancer
  • Lymphoma
  • Small Molecules
  • Thiopurines

Fingerprint

Dive into the research topics of 'AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Patients With Malignancy: Commentary'. Together they form a unique fingerprint.

Cite this